Patents by Inventor Gregory P. Thill

Gregory P. Thill has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20130164851
    Abstract: Provided herein are methods and compositions for generating a cell line capable of producing a biological product, using a gene amplification based system. Methods and compositions are provided to inhibit endogenous selectable amplifiable marker genes using RNA interference and prevent the selection of false positives during generation of a custom cell line. Such methods improve efficiency of cell line development and do not require the use of specialized substrates or cells lacking the endogenous selectable amplifiable marker gene to negate the effect of endogenously expressed levels of the selectable amplifiable marker gene in cells.
    Type: Application
    Filed: March 25, 2011
    Publication date: June 27, 2013
    Applicant: ALNYLAM PHARMACEUTICALS, INC.
    Inventors: Anthony Rossomando, Gregory P. Thill, Stuart Pollard
  • Patent number: 5827684
    Abstract: A method for producing one or more Bacillus toxin polypeptides by culturing methylotrophic yeast cells which have a gene(s) capable of expressing the Bacillus toxin polypeptide(s) in such cells under conditions that the gene(s) is/are transcribed is provided. The toxin polypeptide encoding segment of the gene(s) has a G+C content of about 40%-55%, and preferably comprises methylotrophic yeast codons. The preferred species of yeast for expressing such synthetic Bacillus toxin gene(s) is Pichia pastoris. Bacillus toxin polypeptides encoded by synthetic genes are expressed at high levels in transformed methylotrophic yeast cells. The toxin expressing cells may be administered as live cells or heat-killed whole cells to provide an insecticidal composition for killing susceptible insect larvae.
    Type: Grant
    Filed: April 19, 1994
    Date of Patent: October 27, 1998
    Assignee: Research Corporation Technologies, Inc.
    Inventors: Kotikanyadanam Sreekrishna, William D. Prevatt, Gregory P. Thill, Geneva R. Davis, Patricia Koutz, Kathryn A. Barr, Sharon A. Hopkins
  • Patent number: 5707828
    Abstract: The present invention is directed to expression cassettes comprising a 5' regulatory region from at least one of the Pichia pastoris AOXI gene, p40 gene, DASI gene or HIS4 gene, operably linked to an HSA structural gene including the HSA signal sequence. The HSA structural gene has a translational start codon within 0 to 11 deoxyribonucleotides from the 5' end of the HSA structural gene and is operably linked to a 3' termination sequence. Further, the adenine and thymine content of the intervening deoxyribonucleotides is in the range from about 55 to about 64%. The expression cassette may be an autonomously replicating vector or an integrative vector. Other embodiments of the present invention include Pichia pastoris strains transformed with the HSA expression cassettes and processes for secretion of HSA using the expression cassettes.
    Type: Grant
    Filed: May 3, 1995
    Date of Patent: January 13, 1998
    Assignee: Research Corporation Technologies, Inc.
    Inventors: Kotikanyadan Sreekrishna, Juerg F. Tschopp, Gregory P. Thill, Russell A. Brierley, Kathryn A. Barr
  • Patent number: 5670630
    Abstract: A process for the enhanced production of antigenic particles consisting essentially of hepatitis B S protein and preS.sub.2 protein. Also disclosed are novel DNA molecules and hosts transformed with these molecules.
    Type: Grant
    Filed: June 6, 1995
    Date of Patent: September 23, 1997
    Assignee: Research Corporation Technologies, Inc.
    Inventor: Gregory P. Thill
  • Patent number: 5650296
    Abstract: A process for the enhanced production of antigenic particles consisting essentially of hepatitis B S protein and preS.sub.2 protein. Also disclosed are novel DNA molecules and hosts transformed with these molecules.
    Type: Grant
    Filed: June 6, 1995
    Date of Patent: July 22, 1997
    Assignee: Research Corporation Technologies, Inc.
    Inventor: Gregory P. Thill
  • Patent number: 5102789
    Abstract: Epidermal Growth Factor (EGF) is produced by recombinant DNA technology in Pichia pastoris yeast cells.
    Type: Grant
    Filed: March 15, 1989
    Date of Patent: April 7, 1992
    Assignee: The Salk Institute Biotechnology/Industrial Associates, Inc.
    Inventors: Robert S. Siegel, Richard G. Buckholz, Gregory P. Thill, Lillian M. Wondrack